Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methyldopa
Drug ID BADD_D01425
Description Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent.[A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals.[A1499] Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form.[A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].[L32619] Methyldopa is also available as intravenous injection, which is used to manage hypertension when oral therapy is unfeasible and to treat hypertensive crisis.[L32624]
Indications and Usage For use in the treatment of hypertension.
Marketing Status Prescription; Discontinued
ATC Code C02AB01
DrugBank ID DB00968
KEGG ID D00405
MeSH ID D008750
PubChem ID 38853
TTD Drug ID D0BA6T
NDC Product Code 15894-0038; 42185-7001; 16729-031; 52423-0100; 16729-030; 67628-3001
Synonyms Methyldopa | alpha-Methyldopa | alpha Methyldopa | alpha-Methyl-L-Dopa | alpha Methyl L Dopa | Alphamethyldopa | Meldopa | Methyldopate | Dopegyt | Dopergit | Dopegit | Sembrina | Apo-Methyldopa | Apo Methyldopa | Dopamet | Aldomet | Hydopa | Nu-Medopa | Nu Medopa
Chemical Information
Molecular Formula C10H13NO4
CAS Registry Number 555-30-6
SMILES CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Myalgia15.05.02.001--
Myocarditis02.04.03.001--
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Nightmare19.02.03.003--Not Available
Oedema14.05.06.010; 08.01.07.0060.004706%Not Available
Oligohydramnios18.05.01.0010.011765%Not Available
Orthostatic hypotension17.05.01.020; 24.06.03.004--Not Available
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.003--Not Available
Paradoxical pressor response24.08.02.003--Not Available
Paraesthesia17.02.06.005--
Parkinsonism17.01.05.003--Not Available
Pericarditis02.06.02.001--
Pre-eclampsia24.08.07.002; 20.01.08.002; 18.02.03.0020.004706%Not Available
Premature baby18.04.02.0010.072943%Not Available
Premature delivery18.07.01.0060.042354%
Premature labour18.07.01.0020.018824%Not Available
Premature rupture of membranes18.07.01.0030.004706%Not Available
Premature separation of placenta24.07.03.019; 18.02.01.0040.011765%Not Available
Proteinuria20.02.01.0110.009412%
Pulmonary haemorrhage24.07.01.016; 22.02.04.0030.001228%
Pulmonary hypoplasia22.10.01.002; 03.16.01.0030.001228%Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Respiratory distress22.02.01.0120.001841%Not Available
Rheumatoid factor13.06.01.005--Not Available
Sedation17.02.04.005--Not Available
Seizure17.12.03.0010.004706%
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages